RVXC.F Stock Overview
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Resverlogix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.038 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.034 |
| Beta | 0.72 |
| 1 Month Change | -11.83% |
| 3 Month Change | -21.16% |
| 1 Year Change | -67.91% |
| 3 Year Change | -94.94% |
| 5 Year Change | -98.74% |
| Change since IPO | -97.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| RVXC.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.3% | -2.5% | -3.2% |
| 1Y | -67.9% | -3.7% | 19.3% |
Return vs Industry: RVXC.F underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: RVXC.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| RVXC.F volatility | |
|---|---|
| RVXC.F Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RVXC.F's share price has been volatile over the past 3 months.
Volatility Over Time: RVXC.F's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 19 | Don McCaffrey | www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
Resverlogix Corp. Fundamentals Summary
| RVXC.F fundamental statistics | |
|---|---|
| Market cap | US$10.98m |
| Earnings (TTM) | -US$16.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs RVXC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVXC.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.74m |
| Earnings | -US$16.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -95.2% |
How did RVXC.F perform over the long term?
See historical performance and comparison